Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes
A Dose Escalation Phase I/II Study of Clofarabine Plus Cytarabine With Growth Factor Priming in Patients Who Are Not Felt to be Candidates for More Aggressive Treatment, With Int-2 and High-Risk MDS
Sponsor: National Cancer Institute (NCI)
Terminated
Genzyme discontinued Funding
Other terminated trials from National Cancer Institute (NCI)
Other Myelodysplastic Syndromes trials with similar outcome
This PHASE1/PHASE2 trial investigates Myelodysplastic Syndromes and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 10 recorded versions since 2007 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2023 — Oct 2023 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1_PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2017 — May 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Nebraska
For direct contact, visit the study record on ClinicalTrials.gov .